Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Argenx se save search
argenx to Present at Upcoming September 2023 Investor Conferences
Published: 2023-08-30 (Crawled : 07:00) - biospace.com/
MS | News 0 d | $92.74 0.71% 550K
|
Finance
|
| O: 1.44%
H: 0.0%
C: 0.0%
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 1.45%
H: 0.36%
C: -1.67%
argenx to Present at Upcoming June 2023 Investor Conferences
Published: 2023-05-31 (Crawled : 07:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 0.68%
H: 0.3%
C: -1.6%
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
Published: 2022-11-22 (Crawled : 10:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -0.35%
fda application license review
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
Published: 2022-09-21 (Crawled : 07:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -3.44%
treatment drug application license food
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
Published: 2022-08-11 (Crawled : 17:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 1.76%
H: 0.31%
C: -1.76%
treatment approval
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Published: 2022-06-24 (Crawled : 06:00) - globenewswire.com
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: -0.57%
H: 0.65%
C: 0.52%
treatment europe chmp positive
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
Published: 2022-04-05 (Crawled : 07:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 1.03%
H: 1.06%
C: -1.2%
vyvgart results
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Published: 2022-02-10 (Crawled : 09:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: -0.0%
H: 3.77%
C: 0.46%
health thc conference svb leerink global
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
Published: 2022-01-20 (Crawled : 10:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: -0.44%
H: 1.8%
C: -0.82%
treatment approval
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Published: 2021-08-25 (Crawled : 06:00) - globenewswire.com
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 1.01%
H: 1.08%
C: 0.43%
europe authorized application
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
Published: 2021-07-29 (Crawled : 09:00) - biospace.com/
ZLAB | $15.36 2.47% 140K
|
Health Technology
|
| O: 4.47%
H: 0.97%
C: -8.83%
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: -3.51%
H: 2.44%
C: -0.29%
financial results results
argenx to Present at Upcoming Investor Conferences - June 01, 2021
Published: 2021-06-01 (Crawled : 08:00) - biospace.com/
ARGX | $371.055 0.63% 58K
|
Health Technology
|
| O: 0.35%
H: 0.16%
C: -1.46%
conference presentation
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.46 96.8% 28M
|
Finance
EDBL | News | $6.94 84.57% 1.4M
|
CZOO | $7.74 55.11% 2.7M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
BTCM | $3.41 26.3% 230K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.